Investing.com -- Protara Therapeutics Inc (NASDAQ:TARA) stock fell 10.5% in after-hours trading Thursday following the announcement of a $75 million public offering of common stock and pre-funded warrants.
The clinical-stage biopharmaceutical company, which develops treatments for cancer and rare diseases, said it would offer shares of its common stock or pre-funded warrants to certain investors. All securities in the proposed offering will be sold by Protara.
J.P. Morgan, TD Cowen, and Piper Sandler are serving as joint book-running managers for the offering. Protara also plans to grant underwriters a 30-day option to purchase additional common shares at the public offering price, less underwriting discounts and commissions.
The company intends to use proceeds from the offering to fund clinical development of its TARA-002 program and other clinical initiatives. Funds may also be allocated to working capital and general corporate purposes.
The offering remains subject to market conditions, with no guarantee regarding its completion timeline or final terms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.








